“High-sensitivity CRP has been shown to be an independent marker of risk in addition to and in some cases over and above all ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
D Path, a company dedicated to personalizing cancer care through a novel, physics-inspired approach to predicting tumor response to therapy, today announced its participation as an exploratory ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from ...
Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery market ...
Researchers are debating whether ERAP2 can serve as a reliable ageing-derived biomarker for premature ovarian insufficiency, ...
Clinical trial data demonstrates how Bio-Techne's spatial biology technology and Nucleai's AI-powered multimodal platforms can identify predictive biomarkers in immunotherapy and targeted ...
A third of patients with high-risk prostate cancer identified as biomarker-negative by an artificial intelligence (AI)–derived tool were safe to forgo long-term androgen deprivation therapy (ADT).
The integration of PD-1 inhibitors into standard chemotherapy and radiotherapy regimens has revolutionized nasopharyngeal carcinoma treatment, yet only a minority of patients achieve durable responses ...
Healthcare Asia Magazine on MSN
Predictive clinical biomarkers market could grow 73% to $14.69b by 2030
MarketsandMarkets estimated a CAGR of 11.6% over the five-year period. The global predictive clinical biomarkers market is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results